Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Promyelocytic, Acute 1

Interventions

venetoclax 157Cytarabine 117Cyclophosphamide 110Specimen Handling 103Azacitidine 103fludarabine 89Biopsy 78Rituximab 50Methotrexate 45Daunorubicin 45fludarabine phosphate 41Vincristine 38Dexamethasone 37Injections 36Magnetic Resonance Spectroscopy 35Decitabine 35Granulocyte Colony-Stimulating Factor 32blinatumomab 31Mycophenolic Acid 30Idarubicin 30Whole-Body Irradiation 29ibrutinib 27Tacrolimus 27Prednisone 27Etoposide 27Doxorubicin 27Busulfan 27acalabrutinib 24Melphalan 24Filgrastim 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
arsenous acid × Other hematologic neoplasm × 90 days × Clear all
NCT01409161 2026-05-20

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
151 enrolled
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡